ReviewFrontiers in immunology2017
Complement in Pancreatic Disease-Perpetrator or Savior?
Review in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- Profiling the pancreatic cancer secretome with metabolic glycoengineering.The Journal of biological chemistry · 2026Article
- Remote Pancreatic Response to Severe Polytrauma Correlates With Clinical Outcome.United European gastroenterology journal · 2026Article
- Article
- Bioinformatics and Machine Learning Methods Identified MGST1 and QPCT as Novel Biomarkers for Severe Acute Pancreatitis.Molecular biotechnology · 2024Article
- The Molecular Twin artificial-intelligence platform integrates multi-omic data to predict outcomes for pancreatic adenocarcinoma patients.Nature cancer · 2024Article
- Innate and adaptive immune-directed tumour microenvironment in pancreatic ductal adenocarcinoma.Frontiers in immunology · 2024Review
- Coagulopathy and acute pancreatitis: pathophysiology and clinical treatment.Frontiers in immunology · 2024Review
- The immune response to a fungus in pancreatic cancer samples.bioRxiv : the preprint server for biology · 2023Article
- Monocytic HLA-DR Expression in Immune Responses of Acute Pancreatitis and COVID-19.International journal of molecular sciences · 2023Review
- Targeted and explorative profiling of kallikrein proteases and global proteome biology of pancreatic ductal adenocarcinoma, chronic pancreatitis, and normal pancreas highlights disease-specific proteome remodelling.Neoplasia (New York, N.Y.) · 2023Article
- The inflammatory response of human pancreatic cancer samples compared to normal controls.PloS one · 2023Article
- Pathogenesis and Therapy of Coagulation Disorders in Severe Acute Pancreatitis.Journal of inflammation research · 2023Review
- Complement and Fungal Dysbiosis as Prognostic Markers and Potential Targets in PDAC Treatment.Current oncology (Toronto, Ont.) · 2022Review
- Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment.Nature genetics · 2022Article
- Combined Inhibition of FOSL-1 and YAP Using siRNA-Lipoplexes Reduces the Growth of Pancreatic Tumor.Cancers · 2022Article
- Targeting the complement system in pancreatic cancer drug resistance: a novel therapeutic approach.Cancer drug resistance (Alhambra, Calif.) · 2022Review
- Pancreatic cancer is marked by complement-high blood monocytes and tumor-associated macrophages.Life science alliance · 2021Article
- A case report of recurrent acute pancreatitis associated with life threatening atypical hemolytic uremic syndrome.Medicine · 2020Article
- Risk Stratification and Early Conservative Treatment of Acute Pancreatitis.Visceral medicine · 2019Review
- Auxiliary activation of the complement system and its importance for the pathophysiology of clinical conditions.Seminars in immunopathology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The complement system is a major pillar of the humoral innate immune system. As a first line of defense against pathogens, it mediates early inflammatory response and links different branches of humoral and cellular immunity. Disorders affecting the exocrine pancreas, such as acute pancreatitis, potentially lead to a life-threatening systemic inflammatory response with aberrant activation of complement and coagulation cascades. Pancreatic proteases can activate key effectors of the complement system, which in turn drive local and systemic inflammation. Beyond that, the extent of pancreas-complement interaction covers complex pro- and anti-inflammatory mechanisms, which to this day remain to be fully elucidated. This review provides a comprehensive overview of the pathophysiological role of complement in diseases of the exocrine pancreas, based on existing experimental and clinical data. Participation of complement in acute and chronic pancreatitis is addressed, as well as its role in tumor immunology. Therapeutic strategies targeting complement in these diseases have long been proposed but have not yet arrived in the clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.